Leflunomide (1a) is an isoxazole-containing heterocyclic compound recently approved for the treatment of active rheumatoid arthritis in the U.S.A. 1) Being a prodrug, upon absorption leflunomide quickly converts to its ring-opened isomer malononitrilamide 2 [2] [3] [4] as the active therapeutic agent, which in turn confers immunomodulating activity through the dual mechanisms of selective inhibition of dihydroorotate dehydrogenase 5) and tyrosine kinase 6) and thus suppresses T cell proliferation.
Leflunomide is clinically efficacious, but nevertheless is not free from adverse effects. Its sluggish clearance, caused by the very long plasma half-life (18 d) of 2, 6) and severe liver function impairment have resulted in unusual dose regimens or drug monitoring protocols. These clinical difficulties have prompted intensive efforts to investigate leflunomide analogues, mainly by structural optimization in the phenyl ring, as novel, potent immunomodulating agents with fewer and less severe adverse effects. We report herein their antiinflammatory activity and structure-activity relationships (SARs).
Chemistry Compounds 1a-f were prepared as the patent describes, 7) and compounds 1g-k by our previously method reported. 8) Compound 1l was obtained by hydrolysis of 1k. The active metabolite 2 used as a positive control in the antiinflammatory test was obtained by hydrolysis of 1a. 9, 10) The structures of unpublished 1i (mp 152-154°C), 1k (mp 252-254°C) and 1l (mp 184-186°C) were established by spectroscopy and elemental analysis.
Even though 2 exhibited two conformations in a solventdependent manner, the (Z)-isomer is dominant due to marked stabilization by forming a strong intramolecular hydrogen bond, which was considered crucial in the biological activity.
9) The presence of an intramolecular hydrogen bond of 2 was supported by 1 H-NMR studies in which the 2-hydroxy proton signal appeared as a singlet in the downfield region of the spectrum (d 12.38, DMSO-d 6 ). This was also confirmed by X-ray crystallography 9, 11) and a molecular modeling study 12) in the literature.
Biological Evaluations
The carrageenan-induced paw edema assay 13) in male Sprague-Dawley rats (250Ϯ35 g) was used to evaluate the in vivo antiinflammatory activity. The results, expressed as percent inhibition of the response to carrageenan-induced inflammation, are presented in Tables 1  and 2 . For comparison, dexamethasone and ibuprofen were used. Table 1 shows that leflunomide (1a) demonstrates more activity than ibuprofen, and both exhibit dose-dependent efficacy. The active metabolite 2, as expected, is superior to its parent compound 1a at 10 mg/kg. From Table 2 , it is noteworthy that, compared with leflunomide (1a), nearly all the analogues show higher or similar intraperitoneal activity with the exceptions of nonsubstituted 1b, 2-chloro-substituted 1c and glutamic acid derivatives 1k and 1l.
Our preliminary results show that in the structure modification of leflunomide (1a), introduction of electron-donating substituents such as 4-OCH 3 (1h), 3,4,5-(OCH 3 ) 3 (1i), or negative inductive substituents with a flanking steric hindrance such as 3-Cl (1d), 3-CF 3 (1f), and 2,4-(Cl) 2 (1g) in the aromatic moiety significantly increases the antiinflammatory activity. The nature of the substituents in the 4-position does not seem to influence the activity noticeably, as shown in 1e (4-Cl), 1h (4-OCH 3 ), and 1j (4-COOH). The unsubstituted A series of leflunomide (1a) analogues were examined for antiinflammatory activity using the carrageenaninduced paw edema assay. Some of the compounds were significantly more potent than leflunomide, particularly those with electron-donating or negative inductive groups situated in the phenyl rings. In contrast, all the nonsubstituted compounds or with further chain-extension in the 4-position of the rings led to a decrease in activity. The LD 50 values of the most active compounds (1d, g-j) in male ICR mice were significantly greater than those of either 1a or its active metabolite 2 and therefore merit further study.
Key words antiinflammatory agent; leflunomide; carrageenan-induced paw edema assay a) Edema rate (E %) was calculated as follows: E %ϭ(V t ϪV 0 )/V 0 ϫ100; V 0 : volume of hind paw before 1% carrageenan administration; V t : volume of hind paw after 1% carrageenan administration at t h. Percentage of inhibition (I %) was determined as follows: I %ϭ(E c ϪE t )/E c ϫ100; E c : edema rate of control group; E t : edema rate of test compound at t h. Student's t-test was performed. Each value represents the meanϮS.D. compound 1b and 2-chloro-substituted 1c, on the other hand, were virtually inactive. However, a carboxylic acid group appended in the 4-position of the aromatic ring made 1j as potent as leflunomide. This indicates that the COOH group in 1j ionized in the physiological environment might play a vital role in the requisite drug-receptor complexation through electrostatic interaction. Interestingly, increasing the bulk and the length of the chain of the substituents in the 4-position by extending the carboxylic acid group as part of glutamic acid 1l or its ester 1k, mimicking methotrexate, drastically reduces activity, which might be interpreted as a steric requirement for activity.
Determination of LD 50 Values in Male Mice
Leflunomide (1a) and its metabolite 2 and the most potent products (1d, g-j) were chosen to determine the LD 50 values in male ICR mice (20Ϯ2 g) after intraperitoneal administration of the compounds.
14) The values measured for 1d, 1g, 1h, 1i, and 1j were all 400 mg/kg, which was significantly higher than that of leflunomide (250 mg/kg) and 2 (200 mg/kg). The acute symptoms observed before death included agitation, lacrimation, crawling, trembling, and reduced motility. Cyanosis and deep necrosis were noticed at death in mice that received 1a, 2, and 1i between 1 and 12 h after dosing. This may suggest that structural modification in the phenyl ring of leflunomide might lead to a reduction in toxicity, while the cyanopropenamide moiety in the ring-opened form of the active metabolite 2 might contribute to toxicity. If this is the case, the analogues might also have improved the stability of isoxazole ring. Currently, we are making further modifications in position 3 of the isoxazole ring of leflunomide on the basis of bioisosterism to produce 5-methylisoxazole-3-carboxamides with to study their SARs and stability in the physiological environment further. This investigation is in progress and will be reported shortly.
In conclusion, we have shown that optimization of the phenyl ring of leflunomide offers a method to improve pharmacological profiles and thus suggests approaches to develop new drugs useful in the treatment of inflammatory or immunologic disorders. 
